Showing 1481-1490 of 1616 results for "".
- FDA Authorizes Hand-Held COVID-19 Diagnostic Testhttps://modernod.com/news/fda-authorizes-hand-held-covid-19-diagnostic-test/2477452/In response to the coronavirus crisis, we’ve seen COVID-19 diagnostics quickly evolve from early, multistep kits to high-throughput versions to fast point-of-care tests, all in just a few weeks. Now, the FDA has granted an emergency authorization to a device that fits in the palm of you
- Doctors Turn to Malaria Drugs as Potential Coronavirus Treatmenthttps://modernod.com/news/doctors-turn-to-malaria-drugs-as-potential-coronavirus-treatment/2477434/Doctors and hospitals are turning to chloroquine phosphate and hydroxychloroquine to treat patients infected with COVID-19, as the antimalarial drugs have both shown early signs of improving symptoms of some patients diagnosed with COVID-19, based on reports by doctors and researchers in South Ko
- TECLens Announces Completion of Enrollment of a Pilot Clinical Study for the Treatment of Keratoconushttps://modernod.com/news/teclens-announces-completion-of-enrollment-of-a-pilot-clinical-study-for-the-treatment-of-keratoconus/2476980/TECLens announced the completion of enrollment of its pilot clinical study for the treatment of Keratoconus using the TECLens’ CXLens ‘on-eye’ cross-linking system for corneal remodeling. Clinical trial results are anticipated in early 2020. TECLens’ CXLens will pro
- Center for Vision and Population Health at Prevent Blindness Established to Implement Strategies to Address Eye Healthhttps://modernod.com/news/center-for-vision-and-population-health-at-prevent-blindness-established-to-implement-strategies-to-address-eye-health/2476154/Healthy vision can be a key component to independence and well-being for people of all ages. However barriers such as poor access to eye care, lack of insurance coverage, and inconsistent policies for eye health can prevent early detection and treatment of eye disorders. Prevent Blindness,
- Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-campaign-to-spotlightsight-in-honor-of-world-sight-day/2479805/Sight is the most prized of all human senses. Yet, there are many people who do not fully experience the wonder of this gift. Nearly 285 million people around the world face impaired vision, and 80 percent of those cases are preventable with early diagnosis and treatment. That’s why Johnson
- Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trialhttps://modernod.com/news/aldeyra-therapeutics-announces-positive-results-from-phase-2b-dry-eye-disease-clinical-trial/2479841/Aldeyra Therapeutics announced positive results from its phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease. “The early onset and broad activity observed in the phase 2b clinical trial sugg
- Some Companies Cancel, Reduce Planned Price Hikes Amid Continued Pressure Over US Drug Costs: Reporthttps://modernod.com/news/some-companies-cancel-reduce-planned-price-hikes-amid-continued-pressure-over-us-drug-costs-report/2480031/Novartis, Gilead Sciences, Roche, and Novo Nordisk have advised California health plans in recent weeks that the companies are rescinding or reducing previously announced price increases on at least 10 drugs, Bloomberg reported Tuesday. The moves come after California introduced legislation earli
- Novartis CEO Says Drugmaker’s Deal With Trump Lawyer Was a “Mistake”https://modernod.com/news/novartis-ceo-says-drugmakers-deal-with-trump-lawyer-was-a-mistake/2480155/In an internal email sent to employees, Novartis CEO Vasant Narasimhan apologized for the $1.2-million agreement the company made with President Donald Trump’s private lawyer Michael Cohen early last year in a bid to gain insight into US healthcare policy under the new administration. <
- Adverum Announces Postive LUNA Phase 2 and OPTIC Long-Term Data on Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-announces-postive-luna-phase-2-and-optic-long-term-data-on-gene-therapy-for-wet-amd/2482546/Adverum Biotechnologies has released 52-week topline results from its phase 2 LUNA trial and new 4-year follow-up data from the OPTIC phase 1/2 study on its wet AMD gene therapy candidate Ixo-vec (AAV.7m8-aflibercept). “We are thrilled to report 52-week LUNA d
- Startup Vedere Bio II Shuts Down After Preclinical Studies Fall Shorthttps://modernod.com/news/startup-vedere-bio-ii-shuts-down-after-preclinical-studies-fall-short/2481512/About 2 years after its launch, gene therapy start-up Vedere Bio II is shutting down. The decision comes after preclinical studies did not meet targets. The announcement was made from the company’s chairman Kevin Bitterman and CEO Cyrus Mozayeni. “We had a bold mission, to d